Who we are:

The Canadian Network for Learning Healthcare Systems and Cost-Effective ‘Omics Innovation (CLEO) is a pan-Canadian collaboration for sustainable precision medicine. Our multidisciplinary team comprises of researchers in precision oncology, health economics, health informatics, and health policy, as well as, clinicians, HTA bodies, government regulators, technology developers, and persons with lived experience of cancer.

CLEO is supported by Genome British Columbia / Genome Canada [G05CHS] and our co-funding partners: Genome Quebec, Terry Fox Research Institute, BC Cancer’s Personalized OncoGenomics Program (POG), Institute of Health Economics, Simon Fraser University, Ontario Institute for Cancer Research, Canadian Centre for Applied Research in Cancer Control (ARCC), National Cancer Institute, Krembil Foundation, Australian Research Council, and Roche

What we do:

CLEO’s research evaluates Canada’s 6 key precision oncology initiatives to:

  1. Inform the design of learning healthcare systems (LHS) to enable sustainable cancer care
  2. Advance research that enables value-informed implementation of precision oncology;
  3. Build capacity to deliver actionable recommendations and its benefits into the future
  4. Produce research that yields individual, social, and economic benefits for all Canadians

Through these research efforts, CLEO will deliver:

  1. Life-cycle health technology assessment (LC-HTA) framework and protocols for LHS
  2. Patient-centred blockchain-based secure data sharing platform (SDSP)
  3. Policy guidance on healthcare data management that reflect patient preferences and values
  4. Synthesis of case study findings

Principle Investigators:

Members

Faculty/Leaders

Staff

Rosalie Loewen

Health Economist

Students/Trainees

Ann Hermansen

MSc STUDENT

Steve Kalloger

PhD STUDENT

Projects

Sponsors

Back to top